Avtor/Urednik		Juretić, Dubravka; Krajnović, Vera; Šepetavc, Martina; Petlevski, Roberta; Lukač-Bajalo, Jana
Naslov		Glycosaminoglycans in the development and therapy of diabetic complications
Tip		članek
Vir		Acta Pharm Zagreb
Vol. in št.		Letnik 51, št. 2
Leto izdaje		2001
Obseg		str. 85-94
Jezik		eng
Abstrakt		Glomerular glycosaminoglycans are subject of increasing interest in the investigation of diabetic nephropathy because proteoglycan heparan sulfates make up the polyanionic sites of the glomerular basement membrane and epithelial slit processes with glycoproteins. They serve as the charge barrier maintaining the selective permeability of the renal filter. A defect in the regulation of heparan sulfate production by endothelial, myomedial and mesangial cells determines the susceptibility of diabetic patients to developing proteinuria. Similar changes in heparan sulfate content in the intima of the aortas of patients with diabetes mellitus have been observed, suggesting that the abnormalities in heparan sulfate metabolism are not necessarily restricted to the kidney. Numerous reports showed that heparin and, more generally, heparan sulfate or dermatan sulfate prevent and cure experimental and human diabetic nephropathy. Subcutaneous administration of these glycosaminoglycans protects peritoneal function by affecting the remodeling of the peritoneum in the patient on continuous ambulatory peritoneal dialysis. The long-term potential side-effects of glycosaminoglycan therapy are osteoporosis and bleeding.
Deskriptorji		DIABETIC NEPHROPATHIES PROTEOGLYCANS GLYCOSAMINOGLYCANS HEPARIN HEPARITIN SULFATE DERMATAN SULFATE PERITONEAL DIALYSIS